PRESS RELEASE

The AARDEX and BIOCORP teams are outstanding collaborators, who anticipate the nuances of interventional decentralized clinical trials. They go to great lengths to provide the Trials@Home consortium with technology that is the sine qua non for study participants requiring precise insulin dosing and compliance monitoring, combining BIOCORP’s pen injector add-on Mallya^® with AARDEX^® Group’s Software to improve adherence to medication in a Hybrid Phase IV Diabetes Study.

BIOCORP (FR0012788065 – ALCOR / Eligible PEA‐PME) (Paris:ALCOR), a French company specialized in the design, development, and manufacturing of innovative medical devices, and Belgium-based AARDEXGROUP, the leader in tools for measuring and managing adherence to medication in clinical trials are proud to announce one of their first major joint initiatives that will come live in the upcoming months. Both companies today announced they have been recruited by Trials@Home to take part in a Phase IV study called RADIAL. Trials@Home is a center of excellence for Decentralized Clinical Trials (DCTs), whose members include notably Sanofi, J&J, Pfizer.

They will team up with Sanofi, a global leader in healthcare, to create a digital solution for optimized insulin management, 100 years after the first insulin injection in 1922.

Read the full press release here.